Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Stock Forecast

IOVA's stock price has decreased by -78.05% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 10 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $11.9, which forecasts a 424.23% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $20.

Price Target: $11.9 (+424.23%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.00	$11.9	$14	$20
Change	-11.89%	+424.23%	+516.74%	+781.06%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Apr '25	May '25	Jun '25	Jul '25	Aug '25	Sep '25
Strong Buy	5	4	4	4	4	4
Buy	3	3	3	3	4	4
Hold	1	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	10	10	10	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+781.06%	Aug 19, 2025
Yanan Zhu Wells Fargo	Wells Fargo	Buy Maintains $18 → $14	Buy	Maintains	$18 → $14	+516.74%	Aug 8, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $25 → $20	Strong Buy	Maintains	$25 → $20	+781.06%	Aug 8, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $25	Strong Buy	Maintains	$25	+1,001.32%	Jul 23, 2025
David Dai UBS	UBS	Strong Buy → Hold Downgrades $17 → $2	Strong Buy → Hold	Downgrades	$17 → $2	-11.89%	May 16, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

274.65M

Increased by 67.40%

from 164.07M

Revenue Next Year

429.33M

Increased by 56.32%

from 274.65M

EPS This Year

-1.14

from -1.28

EPS Next Year

-0.65

from -1.14

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	1.19M	164.07M	274.65M	429.33M
Revenue Growth	-	-	-	-	13,698.99%	67.40%	56.32%
EPS	-1.88	-2.23	-2.49	-1.89	-1.28	-1.14	-0.65
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	14	14

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	315.0M	567.4M
Avg	274.7M	429.3M
Low	249.1M	343.0M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	92.0%	106.6%
Avg	67.4%	56.3%
Low	51.8%	24.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-1.05	-0.40
Avg	-1.14	-0.65
Low	-1.23	-0.95

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.